AbbVie Sets Biosimilar Expectations As It Prepares To Take The Plunge On Humira
US Brand Erosion Expected To Be 37% In 2023; Amgen Adalimumab Pricing ‘Not A Surprise’
AbbVie has set out its expectations for US biosimilar competition to Humira this year, predicting 37% brand erosion with pressures ramping up in the second half of 2023 as Amgen’s Amjevita is followed into the market by numerous other adalimumab rivals. Management also commented on pricing dynamics after Amgen offered a dual-discount strategy.
You may also be interested in...
As the firm reported Q2 results, AbbVie management offered some insights into how Humira is standing up against US biosimilar adalimumab competition a little better than expected.
As Amgen and AbbVie reveal first-quarter results, a clearer picture is beginning to emerge of the dynamics for biosimilar competition to Humira in the US. But Amgen is cautioning that Q2 sales of Amjevita may not match initial uptake in Q1.
Celltrion USA’s chief commercial officer Thomas Nusbickel tells Scrip how he’s shaping the South Korean group’s operations ahead of key launches that include assets in the immunology segment. He also weighs in on whether big pharma will stay in the biosimilars game over the long term.